HHS vs RTX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HHS exhibits severe financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total failure across all fundamental health benchmarks. The company is trapped in a cycle of contracting revenues (-15.40% YoY) and negative profitability, with a long-term price collapse of over 73% over three years. While the stock trades at a low Price-to-Book (0.85) and Price-to-Sales (0.11), these metrics appear to be a value trap rather than a discount, given the operational decay. The lack of analyst coverage and neutral insider activity further suggest a lack of institutional confidence.
RTX shows bearish fundamentals based on deterministic rules. Financial strength is stable (F-Score 5/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
HHS vs RTX: Head-to-Head Comparison
This page compares Harte Hanks, Inc. (HHS) and RTX Corporation (RTX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.